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Abstract
Background: Studies that use electronic health databases as research material are getting popular but the influence of a
single electronic health database had not been well investigated yet. The United Kingdom’s General Practice Research
Database (GPRD) is one of the few electronic health databases publicly available to academic researchers. This study
analyzed studies that used GPRD to demonstrate the scientific production and academic impact by a single public health
database.
Methodology and Findings: A total of 749 studies published between 1995 and 2009 with ‘General Practice Research
Database’ as their topics, defined as GPRD studies, were extracted from Web of Science. By the end of 2009, the GPRD had
attracted 1251 authors from 22 countries and been used extensively in 749 studies published in 193 journals across 58 study
fields. Each GPRD study was cited 2.7 times by successive studies. Moreover, the total number of GPRD studies increased
rapidly, and it is expected to reach 1500 by 2015, twice the number accumulated till the end of 2009. Since 17 of the most
prolific authors (1.4% of all authors) contributed nearly half (47.9%) of GPRD studies, success in conducting GPRD studies
may accumulate. The GPRD was used mainly in, but not limited to, the three study fields of ‘‘Pharmacology and Pharmacy’’,
‘‘General and Internal Medicine’’, and ‘‘Public, Environmental and Occupational Health’’. The UK and United States were the
two most active regions of GPRD studies. One-third of GRPD studies were internationally co-authored.
Conclusions: A public electronic health database such as the GPRD will promote scientific production in many ways. Data
owners of electronic health databases at a national level should consider how to reduce access barriers and to make data
more available for research.
Citation: Chen Y-C, Wu J-C, Haschler I, Majeed A, Chen T-J, et al. (2011) Academic Impact of a Public Electronic Health Database: Bibliometric Analysis of Studies
Using the General Practice Research Database. PLoS ONE 6(6): e21404. doi:10.1371/journal.pone.0021404
Editor: Johan Bollen, Indiana University – Bloomington, United States of America
Received November 8, 2010; Accepted June 1, 2011; Published June 22, 2011
Copyright:  2011 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Yu-Chun.Chen@stud.uni-heidelberg.de
Introduction
Electronic health databases have been used widely in health
research in recent decades. Such databases consist of data derived
from routinely collected health records generated by daily clinical
practice. With extremely large case numbers and long observation
periods, electronic health databases have unique potentials in
health research and can be very valuable if made available to
academic researchers [1].
The United Kingdom’s General Practice Research Database
(GPRD) is one of the largest electronic health databases worldwide
[2]. It was established in 1987 as the Value Added Medical
Products (VAMP) Research Databank and transferred to the UK
Department of Health in 1994, which has since then formally
named the database as the General Practice Research Database
(GPRD), ensured data quality, and made it available for academic
research purposes [3].
Currently, the GPRD included around 5 million patients from
around 590 primary care practices throughout the UK. Partici-
pating practices follow an agreed protocol for the collection of
demographic and clinical data and submit anonymised records
regularly using automated extraction to the database. The large
number of patients included in the GPRD, and the accuracy and
completeness of the data, make the database particularly suitable
as a medical research tool [4]. In contrast to the health databases
in other countires, which had restricted access and only limited
contents, the UK made pioneering efforts to make GPRD
publicily avialable to researchers not only in UK but also overseas.
The potential postive influence on academic research could be
anticipated [5]. However, the scope and scale of academic
influence exerted by such electronic health databases have not
yet been well investigated.
This study aimed to analyze GPRD related scientific produc-
tions in terms of the growth of publication numbers, patterns of co-
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publications. If the academic momentum achieved by a single
public health database can be clearly demonstrated, the findings
would serve as a reference for owners of large-scale electronic
health databases in other countries and assist in future research.
Results
Growth of GRPD studies
The first GPRD study appeared as early as 1995, or one year
after the GPRD was renamed and taken over by the Department
of Health in England. A total of 749 GPRD studies published
between 1995 and 2009 (assessed on April 19, 2010) were included
in the analysis; earlier studies using the VAMP database were
excluded from this analysis. By the end of 2009, the GPRD had
attracted 1251 authors from 22 countries and been used
extensively in 749 studies published in 193 journals across 58
study fields (Table 1). Most of the GPRD studies were articles (607,
81%) followed by meeting abstracts (15.5%), proceedings papers
(2.9%) and letters (0.5%).
The number of GPRD studies increased substantially (Table 1).
The average annual growth rate of GPRD studies was 53.3%,
which was considerably higher than the 5.6% of all PubMed
publications and 2.7% of all SCI records between 1997 and 2006
[6]. After the first GPRD study was published in 1995, the number
of GRPD studies rapidly increased following a power law. Power
growth model is an approved method to analyze the publication
dynamics in scientific field [7]. The power growth model was fitted
well with the numbers of the GPRD studies and showed an
increased concave curve (R
2=99.96%). Assuming all influential
environmental factors remained the same for next 5 years, the
number of GPRD studies would more than double in 2015
compared to 2009, with as many as 1646 expected publications.
Fig. 1 shows past and extrapolated research dynamics of GPRD
studies in comparison with studies using other public electronic
health database derived from [8,9,10].
Author productivity patterns
A total of 1251 authors had published 749 GPRD studies at the
end of 2009. Almost all of the studies were co-authored (98.5%,
738/749). The number of authors per study ranged from one to
15, with a median of four. Since the publication of the first GPRD
article in 1995, the most prolific author (Herschel Jick) had
published 79 GPRD studies; the majority of authors (57.0%) had
been involved in only one study until the end of 2009.
The advantages of conducting and publishing GPRD studies
may increase further. The 17 most prolific authors (1.4% of all
authors) contributed nearly half (47.9%) of GPRD studies; 65.6%
of GPRD studies were produced by the 26 most prolific authors
(3.6% of all authors) (Table 2). As the number of GPRD studies
published increased, the number of authors producing these
publications increased more slowly. Such skewed distribution
suggests that the success of publishing GPRD studies was more
reproducible in authors who had successfully previously published
than those who had no or less experience in publication [11].
Expansion in fields of study
The GPRD was applied in a growing number of study fields. In
terms of the Subject Categories defined in SCI, the first GPRD
study was published in field of ‘‘Medicine, General and Internal’’
[12]. Fifteen years later, the number of distinct fields of study had
steadily increased to one-third of all SCI defined Subject
Categories (33.4%, 58/172 Subject Categories) at the end of 2009.
The GPRD was most frequently used in study field of
‘‘Pharmacology and Pharmacy’’, followed by ‘‘Medicine, General
and Internal’’ and ‘‘Public, Environmental and Occupational
Health’’ (26.4%, 14.2%, and 10.5%, respectively) (Table 3). The
three most involved study fields accounted for half (51.5%) of all
GPRD studies whereas the other half of GPRD studies were
spread in 55 different study fields. These findings suggest that the
GPRD had been used widely not only in the three aforementioned
main streams but also in many other fields.
Table 1. Cumulated numbers and average annual growth rates of GPRD studies published between 1995 and 2009.
Year Number of articles Number of authors
Number of Subject
Categories Number of journals Number of countries
1995 3 9 1 3 2
1996 7 16 4 6 2
1997 15 28 6 11 4
1 9 9 8 3 56 41 01 9 7
1999 55 100 13 28 8
2000 98 179 28 49 11
2001 135 230 29 63 11
2002 181 303 31 77 13
2003 227 389 39 99 14
2004 304 508 44 123 15
2005 380 650 48 135 15
2006 464 805 53 150 18
2007 549 942 55 168 19
2008 648 1095 55 178 21
2009 749 1251 58 193 22
Average annual
growth rate (%)
53.3 45.4 45.7 37.8 21.5
doi:10.1371/journal.pone.0021404.t001
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Because of the widespread study fields used in the application
the GPRD, these papers had been broadly published in 193
journals by the end of 2009. The top ten journals published one-
third (33.6%) of all GPRD studies (Table 4). The leading journal,
‘‘Pharmaco-epidemiology and Drug Safety’’, had largest share,
which was more than twice as many as the second journal, ‘‘The
British Journal of Clinical Pharmacology’’.
GPRD studies were influential to successive studies in terms of
citation counts. On average, GPRD studies were cited by more
than 2 articles at the end of 2009 (average citations per
article=2.689). Most (84.4%) of GPRD studies were referenced
by other studies (Table 5). Moreover, 45 GPRD studies have at
least 45 citations; this showed both academic importance and
productivity with the h-index of 45. Both finding suggested
GPRD studies are influential in future research in their topic
areas.
Major national players
A paper is assigned to a country if it is listed as at least one
author’s affiliation. Accordingly, the UK is the most productive
region of contributors: 52.6% of the papers had at least one UK
author. Next is the USA with 41.7%. The ten most productive
countries in terms of absolute number of papers are listed in the
first column of Table 6. They account for 97% of the total number
of GPRD studies (727/749 studies).
To measure the research activity of GPRD studies, the absolute
numbers of GPRD studies were adjusted to the population size of
each country and the numbers of national SCI publications per
thousand inhabitants were calculated as references (Table 6). The
UK benefited most from GRPD studies, jumping from the 5
th
most productive country according to SCI in general to the
number one in GPRD studies. Switzerland and the Netherlands
were also all active and productive in GPRD studies and took a
clear lead over other countries. In consideration of the rank of first
Figure 1. Cumulative numbers of GPRD studies compared with epidemiologic studies using public electronic health database in
Canada, France and Germany. The cumulative numbers of studies published between 1995 and 2009 (solid data points) were fitted well with a
power growth model (solid line). The predicted cumulative numbers of GPRD studies were then extrapolated by the fitted power model (hollow data
points with short dashed line). The extrapolation should be interpreted cautiously under assumption. Data source: Germany: studies using German
health insurance medication claims data [8]; France: studies using French reimbursement databases [9]; Canada: studies using Manitoba and
Saskatchewan administrative health care utilization databases [10].
doi:10.1371/journal.pone.0021404.g001
Table 2. Number of authors and GPRD studies with their cumulative percentage as grouped by number of authored GPRD studies
published between 1995 and 2009.
Number of articles per
author Number of authors
Cumulative percentage
to all authors (%)
Cumulative contribution
to articles
Cumulative percentage to all
GPRD studies (%)
20 or above 17 1.4 359 47.9
19-10 28 3.6 491 65.6
9-2 493 43.0 720 96.1
1 713 100.0 749 100.0
doi:10.1371/journal.pone.0021404.t002
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appeared active but lacking of first authored papers.
Internationally co-authored works
To study the degree of international collaboration, studies were
divided into either internationally co-authored works or domestic
works according to countries of authors’ affiliation addresses. The
national share of internationally co-authored works was calculated
as the proportion of internationally co-authored works by all
publications of a country. England, Scotland, Wales, and North
Ireland were treated as one country. From 1995 to 2009, more
than one-third (35.2%, 264/749) of GPRD studies were
internationally co-authored. The rate of international co-author-
ship was high since before 2007, according to the international
survey by [13], only 10 countries had reached such a degree of
international work. The UK was involved in more than half
(57.5%, 152/264 articles), which meant that nearly 60% of
internationally co-authored GPRD studies had been co-worked
with UK researchers.
Focusing on the 10 most active countries conducting GPRD
studies (Table 6), the national share of internationally co-authored
GPRD studies were substantially high. The national share of
internationally co-authored GPRD studies of the listed countries,
except the UK, was higher than that of their respective country
baselines (Fig. 2). The international collaboration level of these
listed countries was between 40% and 60%, much higher than that
of other countries, thus making the proportion of internationally
co-authored GRPD studies higher. Sweden and Belgium had the
highest share (100%) of internationally co-authored GPRD
studies. This indicated that all of Sweden and Belgium’s GPRD
studies between 1995 and 2009 were internationally co-authored.
Germany (93%) followed by Switzerland (83%), Spain (73%),
France (65%), Canada (64%), and Italy (63%) were also active in
conducting GPRD studies internationally.
The largest contributors of GPRD studies, the UK, had the
lowest national share of international collaboration. This was
because of the size effect of its domestic GPRD studies. Despite the
large number of internationally co-authored studies, there were
still many GPRD studies produced by UK researchers alone.
Discussion
The GPRD is used widely internationally. However, its
influence had not been well investigated. This study extracted
GPRD studies published between 1995 and 2009 from the SCI
and analyzed the growing influence of GPRD studies from four
different perspectives. In terms of number of studies, the rapid
increase is in a power growth fashion. Observing author
productivity patterns, the findings suggest that the success of
conducting GPRD studies is self-sustaining. The GPRD is used
widely in numerous study fields and not limited to general
Table 3. Top 10 fields of study ranked by number of GPRD studies published between 1995 and 2009.
Field of study Number of articles Share of all GPRD studies (%) Number of distinct journals
Pharmacology & Pharmacy 198 26.4 17
Medicine, General & Internal 106 14.2 20
Public, Environmental & Occupational Health 79 10.5 21
Gastroenterology & Hepatology 50 6.7 12
Endocrinology & Metabolism 47 6.3 11
Clinical Neurology 42 5.6 18
Rheumatology 39 5.2 7
Respiratory System 30 4.0 6
Obstetrics & Gynecology 25 3.3 9
Psychiatry 23 3.1 11
doi:10.1371/journal.pone.0021404.t003
Table 4. Top 10 journals ranked by number of GPRD studies published between 1995 and 2009.
Journal name Number of articles Share of all GPRD studies (%)
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 99 13.2
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 39 5.2
BRITISH MEDICAL JOURNAL 23 3.1
PHARMACOTHERAPY 17 2.3
BRITISH JOURNAL OF GENERAL PRACTICE 15 2.0
EPIDEMIOLOGY 14 1.9
AMERICAN JOURNAL OF EPIDEMIOLOGY 12 1.6
GASTROENTEROLOGY 11 1.5
RHEUMATOLOGY 11 1.5
THORAX 11 1.5
doi:10.1371/journal.pone.0021404.t004
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importantly, GPRD studies showed substantial influence on
successive studies.
There are some limitations in this study. First, the analysis
aimed at demonstrating the resulting impact of GPRD as a
publicly available research material. The observation is primarily
based on historical data during last 15 years. Since there are many
factors that may substantially influence scientific production,
interpretation or extrapolation of our data should be done with
caution. Second, to make the results comparable, only GPRD
studies indexed in the Thomson’s SCI were included in the
analysis. This considerably underestimated the overall scientific
output related to GPRD. If un-indexed studies, such as posters and
abstracts, were included, the output related to GPRD should be
much higher. Third, only studies that mentioned ‘‘GPRD’’ were
included, but not those that used its antecedent, the VAMP
Research Databank. If the latter was taken into account, the
earliest publication could be traced as early as 1988, according to
the GPRD bibliography [14].
The UK’s GPRD, with its extremely large patient numbers and
long observation period, is becoming important in health research
[15,16]. The increase in number of GPRD studies is dramatic,
compared to a previous study [17] and the number of scientific
outputs usually doubles every 10 to 20 years. The authors are not
aware of any scientific discipline with this order of magnitude of
duplication time of only six years. Similarly, rapid growth is also
reported in epidemiologic studies using electronic health databases
worldwide, such as Medicare data in the US [18], Manitoba and
Saskatchewan province database in Canada [10], National Health
Insurance Research Database (NHIRD) in Taiwan [19,26], and
health insurance data in Germany [8], and France [9]. The
findings suggest that electronic medical record databases are used
actively in current health research.
This study clearly demonstrates academic benefits from the
GPRD. While most electronic health databases are used in
pharmaco-epidemiologic studies [20], the GPRD has not limited
its use to a single field. As an electronic medical record system, it
includes basic demographic details, medical records, drug history,
and prevention records. In addition to its comprehensive contents,
linkages to external registries are also made possible by
sophisticated encryption procedures [4]. Furthermore, substantial
efforts have been made to improve data quality and validity [21].
These characteristics make the results of GPRD studies compa-
rable to clinical trials [22] and explain GPRD’s widespread
utilization in various study fields.
Considerable efforts are needed to use GPRD for academic
research. Since the GPRD is primarily designed for data captured
from daily clinical practice, researchers should be highly
knowledgeable about each step of the data collecting process
and carefully tailor the data for their research problems [21]. This
provides an explanation why most GPRD studies are results of co-
work and the unbalanced distribution of authors’ patterns of
outputs. Researchers are prone to work closely with knowledge-
able people about every detail of GPRD to share technology and
experience [20,23]. Attempts are now being made to overcome
technical barriers to conduct more GPRD studies [24,25]. If these
efforts make GPRD more accessible to researchers, an even more
prominent growth in GPRD studies can be expected.
Our analysis demonstrated that a small percentage of authors
contributed to the majority of GPRD studies. A closer look of these
highly productive groups and authors shows that the value of
GPRD’s public availability has boosted their productivity. GPRD
studies are an alternative approach to achieve as meaningful
results as clinical trials without the necessity to invest the good
clinical practice (GCP) driven efforts necessary for each and every
Table 5. Citation counts of GPRD studies published between
1995 and 2009.
Citation counts
a Number of articles
Share of all GPRD studies
(%)
51–70 70 9.3
31–40 131 17.5
21–30 222 29.6
11–20 152 20.3
1–10 57 7.6
0 117 15.6
aCitation counts were calculated as numbers of articles that citing GPRD studies.
doi:10.1371/journal.pone.0021404.t005
Table 6. Countries that published more than 15 GPRD studies between 1995 and 2009 ranked by the number of GPRD studies per
million inhabitants.
Country Number of GPRD studies
Number of GPRD studies per
million inhabitants
Number of national SCI
publications per 1000
inhabitants
Number of first authored-
GPRD studies
UK 394 (1) 6.4 (1) 1.35 (5) 327 (1)
SWITZERLAND 45 (5) 5.9 (2) 2.80 (1) 38 (5)
NETHERLANDS 87 (3) 5.2 (3) 1.63 (3) 44 (4)
SWEDEN 43 (6) 4.7 (4) 1.97 (2) 5 (9)
SPAIN 70 (4) 1.7 (5) 1.00 (7) 54 (3)
CANADA 39 (7) 1.2 (6) 1.44 (4) 20 (6)
USA 281 (2) 0.9 (7) 0.99 (8) 209 (2)
FRANCE 21 (8) 0.3 (8) 0.93 (9) 9 (7)
ITALY 15 (10) 0.3 (8) 0.86 (10) 5 (9)
GERMANY 20 (9) 0.2 (10) 1.04 (6) 9 (7)
Values in parentheses are rankings. SCI, Scientific Citation Index.
doi:10.1371/journal.pone.0021404.t006
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of similar origin improve in efficiency and efficacy with every
successful study established. As automatic procedures are con-
ceived and shared among cooperating institutions, each individual
study competence builds. Therefore the costs and manpower of
each study will likely to decrease. In other words, the ‘‘success
breeds success’’ phenomenon which in its original interpretation in
scientometrics emphasizes individual competence correlates to
related individual success [11] transforms into a societal ‘‘success
breeds success’’ phenomenon: society gets out ever more once a
scientific community has got ‘‘over the hump’’ of mastering the
initial intricacies of getting the right data in the right quality out of
a health care delivery (such as GPRD) or claims database [26].
The most distinguishing feature of GPRD from other
nationwide electronic health databases is its international co-
author pattern. The analysis shows that the GPRD is used actively
by means of international co-work. Such a high share of
international co-authorship reflects a universal demand for large
scale electronic health databases. This should encourage national-
or institutional-level data holders to consider re-using their
electronic health databases for academic purposes. Moreover, an
international strategy not only effectively promotes academic
activities but also provides important opportunities for the
reciprocal exchange of research knowledge among countries [4].
Conclusion
Based on a quantified analysis of the influence of GPRD use, a
public electronic health database can promote scientific produc-
tion in many ways. To promote academic research and health
care, data owners of electronic health databases at a national level
should consider how to reduce access barriers and to make data
more available for research. The increasing use of electronic
patient records worldwide will make more data available for
secondary analysis, subject to legal and technical challenges in
accessing clinical data being addressed. These data have great
potential as research tools and can help in maximizing the outputs
from the large investments being made by many health systems in
the development of electronic patient records and eHealth
systems.
Materials and Methods
To measure the scientific production exerted by the GPRD,
studies used GPRD were extracted and analyzed. Publications
from 1990 to 2010 in the Science Citation Index (SCI) of the
Thomson Scientific’s Institute for Scientific Information (also
known as Thomson’s ISI, Philadelphia, PA, USA) were used as the
main data source. Documents recorded as article, letter, note,
proceedings paper, or meeting abstract were considered. Publica-
tions with GPRD or ‘‘General Practice Research Database’’ as
their topics were defined as GPRD studies and extracted for
further analysis. Publications that used the VAMP Research
Databank, the precursor of GPRD, were not included in the
analysis.
Each GPRD study was assigned into at least one study field
based on the article’s Subject Categories defined in the SCI.
Authors were identified using the author names in last-name-plus-
initial form as recorded in the SCI. Papers were assigned to
countries according to the affiliation addresses of authors. All
countries listed in the address were considered. A paper was
considered as an internationally co-authored work if assigned to
more than one country. National share of internationally co-
authored publications was calculated by the number of interna-
tionally co-authored work divided by the number of GPRD studies
of the given country.
To measure the academic impact of GPRD studies to successive
studies, citation counts at the end of 2009 were included in this
analysis. Average citation count per publication was calculated by
the number of publications that citing these GPRD studies divided
by the number of GPRD studies. The H-index is also calculated to
demonstrate the importance and productivity of GPRD studies
[27].
Figure 2. National share of internationally co-authored SCI studies and GPRD studies by countries. National share of internationally co-
authored publications was calculated by the number of internationally co-authored work divided by the number of GPRD studies or SCI studies of the
given country. As comparison reference values, the national share of internationally co-authored nationwide publications published in 2009 and
indexed in the Scientific Citation Index Expand of given countries are plotted and abbreviated as SCI studies (Accessed 12 May 2010.).
doi:10.1371/journal.pone.0021404.g002
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countries in relation to country sizes, the number of SCI
publications and internationally co-authored SCI publications of
given countries in 2009 were obtained from the Web of ScienceH.
The number of inhabitants per country in 2009 was extracted
from the World Factbook 2009, the official statistic report from the
US government [28]. Microsoft SQL server 2008, together with
Microsoft Excel 2007, was used for data processing and
calculations.
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